EUVIMEDEUVIMED entdecken
Crossref

Oncological outcomes of concurrent chemoradiotherapy with docetaxel, cisplatin, and 5‐fluorouracil for locally advanced squamous cell carcinoma of the external auditory canal: A single‐center study

Akihiro Yamada, Hirotaka Shinomiya iD, Natsumi Uehara iD, Keisuke Iritani iD, Shun Tatehara, Tatsuya Furukawa iD, Masanori Teshima iD, Daisuke Miyawaki, Takeshi Fujita iD, Akinobu Kakigi, Naomi Kiyota iD, Ryohei Sasaki und 1 weitere

Head & Neck · 2023

DOI: 10.1002/hed.27461 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Head & Neck, 2023. Verfasst von Akihiro Yamada und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology - Head and Neck Surgery, Kobe University Graduate School of Medicine, Kobe, Japan. Hauptthemen laut MEDLINE: Head and Neck Neoplasms, Carcinoma, Squamous Cell. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 25 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Squamous cell carcinoma of the external auditory canal (EACSCC) is a rare condition. However, a standard treatment has not yet been established. We retrospectively evaluated the efficacy, adverse events, and feasibility of TPF‐CCRT (concomitant chemoradiotherapy with docetaxel, cisplatin, and 5‐fluorouracil) in patients with advanced EACSCC.

Methods

Thirty‐five consecutive patients with advanced EACSCC (T3, T4) initially treated with TPF‐CCRT at Kobe University Hospital were included. T4 diseases with invasion of the brain, internal carotid artery, or internal jugular vein were classified as T4b, and those without these features were classified as T4a.

Results

Five‐year overall survival rates for T3 and T4 were 100% and 64.2%, respectively. A significant difference was observed between T4a and T4b (82.4% vs. 30%, p = 0.007). Five‐year progression‐free survival rates of T3, T4a, and T4b were 100%, 68%, and 20% ( p = 0.022), respectively.

Conclusions

TPF‐CCRT should be considered as a plausible treatment option for advanced EACSCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Head and Neck NeoplasmsCarcinoma, Squamous CellHumansDocetaxelFluorouracilCisplatinRetrospective StudiesEar CanalTaxoidsAntineoplastic Combined Chemotherapy ProtocolsChemoradiotherapy

Stichwörter der Autor:innen

chemoradiotherapycisplatindocetaxelear cancerfluorouraciltemporal bone

Substanzen

DocetaxelFluorouracilCisplatinTaxoids

Autor:innen und Institutionen

  • Department of Otolaryngology - Head and Neck Surgery, Kobe University Graduate School of Medicine, Kobe, Japan.
  • Department of Radiation Oncology, Kobe University Graduate School of Medicine, Kobe, Japan.
  • Kobe University Hospital Cancer Center, Kobe, Japan.

ORCID-Profile: Hirotaka Shinomiya, Natsumi Uehara, Keisuke Iritani, Tatsuya Furukawa, Masanori Teshima, Takeshi Fujita, Naomi Kiyota, Ken-Ichi Nibu

Zitieren

APA

Yamada, A., Shinomiya, H., Uehara, N., Iritani, K., Tatehara, S., Furukawa, T., Teshima, M., Miyawaki, D., Fujita, T., Kakigi, A., Kiyota, N., Sasaki, R., & Nibu, K. I. (2023). Oncological outcomes of concurrent chemoradiotherapy with docetaxel, cisplatin, and 5‐fluorouracil for locally advanced squamous cell carcinoma of the external auditory canal: A single‐center study. Head & Neck. https://doi.org/10.1002/hed.27461

Vancouver

Yamada A, Shinomiya H, Uehara N, Iritani K, Tatehara S, Furukawa T, et al. Oncological outcomes of concurrent chemoradiotherapy with docetaxel, cisplatin, and 5‐fluorouracil for locally advanced squamous cell carcinoma of the external auditory canal: A single‐center study. Head & Neck. 2023. doi:10.1002/hed.27461

BibTeX
@article{Yamada2023,
  author = {Yamada, Akihiro and Shinomiya, Hirotaka and Uehara, Natsumi and Iritani, Keisuke and Tatehara, Shun and Furukawa, Tatsuya and Teshima, Masanori and Miyawaki, Daisuke and Fujita, Takeshi and Kakigi, Akinobu and Kiyota, Naomi and Sasaki, Ryohei and Nibu, Ken-Ichi},
  title = {Oncological outcomes of concurrent chemoradiotherapy with docetaxel, cisplatin, and 5‐fluorouracil for locally advanced squamous cell carcinoma of the external auditory canal: A single‐center study},
  journal = {Head & Neck},
  year = {2023},
  doi = {10.1002/hed.27461}
}
Kostenlos starten →